Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Rizzo, Daniela ^a   Ruggiero, Antonio ^a   Martini, Maurizio ^b   Rizzo, Valentina ^a   Maurizi, Palma ^a   Riccardi, Riccardo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HISTONE H3; IMATINIB; IRINOTECAN; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN P53; TEMOZOLOMIDE; VASCULOTROPIN; TUMOR MARKER; TUMOR PROTEIN;

ATRX GENE; CANCER PROGNOSIS; CANCER THERAPY; CHILDHOOD CANCER; DNA METHYLATION; EVENT FREE SURVIVAL; GENE; GENETIC DISORDER; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; FEMALE; GENETICS; INFANT; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; INFANT; MALE; NEOPLASM PROTEINS;

EID: 84942794222     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/215135     Document Type: Review

References (83)

1. D. Faury, A. Nantel, S. E. Dunn et al., "Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors," Journal of Clinical Oncology, vol. 25, no. 10, pp. 1196-1208, 2007.
2. A. Broniscer and A. Gajjar, "Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist," Oncologist, vol. 9, no. 2,pp. 197-206, 2004.
3. R. Stupp, W. P. Mason, M. J. van den Bent et al., "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma," The New England Journal of Medicine, vol. 352, no. 10, pp. 987-996, 2005.
4. K. J. Cohen, I. F. Pollack, T. Zhou et al., "Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group," Neuro-Oncology, vol. 13, no. 3, pp. 317-323, 2011.
5. L. S. Lashford, P. Thiesse, A. Jouvet et al., "Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study," Journal of Clinical Oncology, vol. 20, no. 24, pp. 4684-4691, 2002.
6. A. Broniscer, M. Chintagumpala, M. Fouladi et al., "Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children," Journal of Neuro-Oncology, vol. 76, no. 3, pp. 313-319, 2006.
7. A. Ruggiero, G. Cefalo, M. L. Garré et al., "Phase II trial of temozolomide in children with recurrent high-grade glioma," Journal of Neuro-Oncology, vol. 77, no. 1, pp. 89-94, 2006.
8. H. S. Nicholson, C. S. Kretschmar, M. Krailo et al., "Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group," Cancer, vol. 110, no. 7, pp. 1542-1550, 2007.
9. K. J. Cohen, R. L. Heideman, T. Zhou et al., "Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report fromthe Children'sOncologyGroup," Neuro-Oncology, vol. 13, no. 4, pp. 410-416, 2011.
10. E. A. Maher, F. B. Furnari, R. M. Bachoo et al., "Malignant glioma: genetics and biology of a grave matter," Genes & Development, vol. 15, no. 11, pp. 1311-1333, 2001.
11. B. S. Paugh, C. Qu, C. Jones et al., "Integratedmolecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease," Journal of Clinical Oncology, vol. 28, no. 18, pp. 3061-3068, 2010.
12. T. J. MacDonald, D. Aguilera, and C. M. Kramm, "Treatment of high-grade glioma in children and adolescents," Neuro-Oncology, vol. 13, no. 10, pp. 1049-1058, 2011.
13. R. Stupp, M. Gander, S. Leyvraz, and E. Newlands, "Current and future developments in the use of temozolomide for the treatment of brain tumours," The Lancet Oncology, vol. 2, no. 9, pp. 552-560, 2001.
14. M. Esteller, J. Garcia-Foncillas, E. Andion et al., "Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents," The New England Journal of Medicine, vol. 343, no. 19, pp. 1350-1354, 2000.
15. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., "MGMT gene silencing and benefit from temozolomide in glioblastoma," The New England Journal of Medicine, vol. 352, no. 10, pp. 997-1003, 2005.
16. M. Eoli, F. Menghi, M. G. Bruzzone et al., "Methylation of O6-methylguanine DNA methytransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival," Clinical Cancer Research, vol. 13, no. 9, pp. 2606-2613, 2007.
17. I. F. Pollack, R. L. Hamilton, R. W. Sobol et al., "O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort," Journal of Clinical Oncology, vol. 24, no. 21, pp. 3431-3437, 2006.
18. A. M. Donson, S. O. Addo-Yobo, M. H. Handler, L. Gore, and N. K. Foreman, "MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma," Pediatric Blood and Cancer, vol. 48, no. 4, pp. 403-407, 2007.
19. F. R. Buttarelli, M. Massimino, M. Antonelli et al., "Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas," Child's Nervous System, vol. 26, no. 8, pp. 1051-1056, 2010.
20. A. Srivastava, A. Jain, P. Jha et al., "MGMT gene promoter methylation in pediatric glioblastomas," Child's Nervous System, vol. 26, no. 11, pp. 1613-1618, 2010.
21. S. Schlosser, S.Wagner, J.M.Hlisch et al., "MGMTas a potential stratificationmarker in relapsed high-grade glioma of children: the HIT-GBM experience," Pediatric Blood & Cancer, vol. 54, no. 2, pp. 228-237, 2010.
22. J. Y. Lee, C.-K. Park, S.-H. Park, K.-C. Wang, B.-K. Cho, and S.-K. Kim, "MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA," Child's Nervous System, vol. 27, no. 11, pp. 1877-1883, 2011.
23. N. Shinojima, K. Tada, S. Shiraishi et al., "Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme," Cancer Research, vol. 63, no. 20, pp. 6962-6970, 2003.
24. T. A. Libermann, H. R. Nusbaum, N. Razon et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," Nature, vol. 313, no. 5998, pp. 144-147, 1985.
25. I. F. Pollack, R. L. Hamilton, C. D. James et al., "Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort," Journal of Neurosurgery, vol. 105, no. 5, pp. 418-424, 2006.
26. D. A. Bax, N. Gaspar, S. E. Little et al., "EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines," Clinical Cancer Research, vol. 15, pp. 5753-5761, 2009.
27. I. K. Mellinghoff, M. Y. Wang, I. Vivanco et al., "Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors," The New England Journal of Medicine, vol. 353, no. 19, pp. 2012-2024, 2005.
28. I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel, "PTENmediated resistance to epidermal growth factor receptor kinase inhibitors," Clinical Cancer Research, vol. 13,no. 2 I, pp. 378-381, 2007.
29. M. D. Prados, K. R. Lamborn, S. Chang et al., "Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma," Neuro-Oncology, vol. 8, no. 1, pp. 67-78, 2006.
30. W. K. A. Yung, J. J. Vredenburgh, T. F. Cloughesy et al., "Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study," Neuro-Oncology, vol. 12,no. 10,pp. 1061-1070, 2010.
31. A. Broniscer, S. J. Baker, C. F. Stewart et al., "Phase Ii and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma," Clinical Cancer Research, vol. 15, no. 2, pp. 701-707, 2009.
32. R. I. Jakacki, M. Hamilton, R. J. Gilbertson et al., "Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a children's oncology group phase I consortium study," Journal of Clinical Oncology, vol. 26, no. 30, pp. 4921-4927, 2008.
33. B.Geoerger, D. Hargrave,F.Thomas et al., "Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors," Neuro-Oncology, vol. 13, no. 1, pp. 109-118, 2011.
34. D. A. Haas-Kogan, M. D. Prados, T. Tihan et al., "Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib," Journal of the National Cancer Institute, vol. 97, no. 12, pp. 880-887, 2005.
35. M.-E. Halatsch, S. Löw, T. Hielscher, U. Schmidt, A. Unterberg, and V. I. Vougioukas, "Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib," Anticancer Research, vol. 28, no. 6A, pp. 3725-3728, 2008.
36. D. Wang, H.-J. S. Huang, A. Kazlauskas, and W. K. Cavenee, "Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase," Cancer Research, vol. 59, no. 7, pp. 1464-1472, 1999.
37. A. Erlandsson, M. Enarsson, and K. Forsberg-Nilsson, "Immature neurons from CNS stem cells proliferate in response to platelet-derived growth factor," Journal of Neuroscience, vol. 21, no. 10, pp. 3483-3491, 2001.
38. N.A. Lokker, C. M. Sullivan, S. J. Hollenbach,M.A. Israel, and N. A. Giese, "Platelet-derived growth factor (PDGF) autocrine signaling regulates survival andmitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors," Cancer Research, vol. 62, no. 13, pp. 3729-3735, 2002.
39. M. Maxwell, S. P. Naber, H. J. Wolfe et al., "Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance," The Journal of Clinical Investigation, vol. 86, no. 1, pp. 131-140, 1990.
40. F. S. Vassbotn, A. Östman, N. Langeland et al., "Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line," Journal of Cellular Physiology, vol. 158, no. 2, pp. 381-389, 1994.
41. B. S. Paugh, A. Broniscer, C. Qu et al., "Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma," Journal of Clinical Oncology, vol. 29, no. 30, pp. 3999-4006, 2011.
42. S. Puget, C. Philippe, D. A. Bax et al., "Mesenchymal transition and pdgfra amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas," PLoS ONE, vol. 7, no. 2,Article ID e30313, 2012.
43. M. Zarghooni,U. Bartels, E. Lee et al., "Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights plateletderived growth factor receptor α and poly (ADP-ribose) polymerase as potential therapeutic targets," Journal of Clinical Oncology, vol. 28, no. 8, pp. 1337-1344, 2010.
44. D. A. Bax, A. Mackay, S. E. Little et al., "A distinct spectrum of copy number aberrations in pediatric high-grade gliomas," Clinical Cancer Research, vol. 16, no. 13, pp. 3368-3377, 2010.
45. B. S. Paugh, X. Zhu, C. Qu et al., "Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas," Cancer Research, vol. 73, no. 20, pp. 6219-6229, 2013.
46. J. Schwartzentruber, A. Korshunov, X.-Y. Liu et al., "Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma," Nature, vol. 482, no. 7384, pp. 226-231, 2012.
47. F. B. Furnari, T. Fenton, R. M. Bachoo et al., "Malignant astrocytic glioma: genetics, biology, and paths to treatment," Genes and Development, vol. 21, no. 21, pp. 2683-2710, 2007.
48. E. Raymond, A. A. Brandes, C. Dittrich et al., "Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European organisation for research and treatment of cancer brain tumor group study," Journal of ClinicalOncology, vol. 26, no. 28, pp. 4659-4665, 2008.
49. P. Y. Wen, W. K. A. Yung, K. R. Lamborn et al., "Phase I/II study of imatinib mesylate for recurrent malignant gliomas: north American brain tumor consortiumstudy 99-08," Clinical Cancer Research, vol. 12, no. 16, pp. 4899-4907, 2006.
50. D. A. Reardon, M. J. Egorin, J. A. Quinn et al., "Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme," Journal of Clinical Oncology, vol. 23, pp. 9359-9368, 2005.
51. I. F. Pollack, R. I. Jakacki, S. M. Blaney et al., "Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report," Neuro-Oncology, vol. 9, no. 2, pp. 145-160, 2007.
52. J. S. Smith, I. Tachibana, S. M. Passe et al., "PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme," Journal of the National Cancer Institute, vol. 93, no. 16, pp. 1246-1256, 2001.
53. C. Raffel, L. Frederick, J. R.O'Fallon et al., "Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations," Clinical Cancer Research, vol. 5, no. 12, pp. 4085-4090, 1999.
54. J. A. Kraus, J. Felsberg, J. C. Tonn, G. Reifenberger, and T. Pietsch, "Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood," Neuropathology and Applied Neurobiology, vol. 28, no. 4, pp. 325-333, 2002.
55. I. F. Pollack, R. L.Hamilton, P. C. Burger et al., "Akt activation is a common event in pediatricmalignant gliomas and a potential adverse prognosticmarker: a report fromthe Children's Oncology Group," Journal of Neuro-Oncology, vol. 99, no. 2, pp. 155-163, 2010.
56. N. Oka, A. Soeda, A. Inagaki et al., "VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells," Biochemical and Biophysical Research Communications, vol. 360, no. 3, pp. 553-559, 2007.
57. S. P. Leon, R. D. Folkerth, and P. M. Black, "Microvessel density is a prognostic indicator for patients with astroglial brain tumors," Cancer, vol. 77, no. 2, pp. 362-372, 1996.
58. N. O. Schmidt, M.Westphal, C. Hagel et al., "Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis," International Journal of Cancer, vol. 84, pp. 10-18, 1999.
59. Y.-H. Zhou, F. Tan, K. R. Hess, and W. K. A. Yung, "The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival," Clinical Cancer Research, vol. 9, no. 9, pp. 3369-3375, 2003.
60. D. Schiff and B. Purow, "Bevacizumab in combination with irinotecan for patients with recurrent glioblastomamultiforme: commentary," Nature Clinical Practice Oncology, vol. 5, no. 4, pp. 186-187, 2008.
61. M. C. Chamberlain, "Bevacizumab plus irinotecan in recurrent glioblastoma," Journal of Clinical Oncology, vol. 26, no. 6, pp. 1012-1013, 2008.
62. J. J. Vredenburgh, A. Desjardins, J. E. Herndon II et al., "Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma," Clinical Cancer Research, vol. 13, no. 4, pp. 1253-1259, 2007.
63. A. Lai, E. Filka, B. McGibbon et al., "Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability," International Journal of Radiation Oncology, Biology, Physics, vol. 71, no. 5, pp. 1372-1380, 2008.
64. S.Gururangan, S. N. Chi, T. Y. Poussaint et al., "Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study," Journal of Clinical Oncology, vol. 28, no. 18, pp. 3069-3075, 2010.
65. A. Narayana, S. Kunnakkat, J. Chacko-Mathew et al., "Bevacizumab in recurrent high-grade pediatric gliomas," Neuro-Oncology, vol. 12, no. 9, pp. 985-990, 2010.
66. C. Parekh, R. Jubran, A. Erdreich-Epstein et al., "Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen," Journal of Neuro-Oncology, vol. 103, no. 3, pp. 673-680, 2011.
67. I. F. Pollack, S. D. Finkelstein, J. Burnham et al., "Age and TP53 mutation frequency in childhood malignant gliomas: results in amulti-institutional cohort," Cancer Research, vol. 61,no. 20,pp. 7404-7407, 2001.
68. I. F. Pollack, S. D. Finkelstein, J. Woods et al., "Expression of p53 and prognosis in childrenwithmalignant gliomas,"TheNew England Journal of Medicine, vol. 346, no. 6, pp. 420-427, 2002.
69. J. A. Simon and R. E. Kingston, "Mechanisms of polycomb gene silencing: knowns and unknowns," Nature Reviews Molecular Cell Biology, vol. 10, no. 10, pp. 697-708, 2009.
70. G. Wu, A. Broniscer, T. A. McEachron et al., "Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas," Nature Genetics, vol. 44, no. 3, pp. 251-253, 2012.
71. D. Sturm, H. Witt, V. Hovestadt et al., "Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma," Cancer Cell, vol. 22, no. 4, pp. 425-437, 2012.
72. D.-A. Khuong-Quang, P. Buczkowicz, P. Rakopoulos et al., "K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas," Acta Neuropathologica, vol. 124, no. 3, pp. 439-447, 2012.
73. G. H.Gielen,M.Gessi, J.Hammes, C. M. Kramm, A.Waha, and T. Pietsch, "H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas," The American Journal of Clinical Pathology, vol. 139, no. 3, pp. 345-349, 2013.
74. A.Dhayalan, R. Tamas, I. Bock et al., "TheATRX-ADDdomain binds to H3 tail peptides and reads the combined methylation state of K4 and K9," Human Molecular Genetics, vol. 20, no. 11, pp. 2195-2203, 2011.
75. C.M.Heaphy, R. F. deWilde, Y. Jiao et al., "Altered telomeres in tumors with ATRX and DAXXmutations," Science, vol. 333, no. 6041, article 425, 2011.
76. B.Wiestler,D. Capper, T.Holland-Letz et al., "ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis," Acta Neuropathologica, vol. 126, no. 3, pp. 443-451, 2013.
77. S. Zhao, Y. Lin,W. Xu et al., "Glioma-derivedmutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α," Science, vol. 324, no. 5924, pp. 261-265, 2009.
78. S. Nobusawa, T. Watanabe, P. Kleihues, and H. Ohgaki, "IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas," Clinical Cancer Research, vol. 15, no. 19, pp. 6002-6007, 2009.
79. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling, "Analysis of the IDH1 codon 132 mutation in brain tumors," Acta Neuropathologica, vol. 116, no. 6, pp. 597-602, 2008.
80. H. Yan, D.W. Parsons, G. Jin et al., "IDH1 and IDH2 mutations in gliomas,"The New England Journal of Medicine, vol. 360, no. 8, pp. 765-773, 2009.
81. M. Antonelli, F. R. Buttarelli, A. Arcella et al., "Prognostic significance of histological grading, p53 status,YKL-40 expression, and IDH1mutations in pediatric high-grade gliomas," Journal of Neuro-Oncology, vol. 99, no. 2, pp. 209-215, 2010.
82. C. Hartmann, J. Meyer, J. Balss et al., "Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas," Acta Neuropathologica, vol. 118, no. 4, pp. 469-474, 2009.
83. I. F. Pollack, R. L. Hamilton, R.W. Sobol et al., "IDH1mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group," Child's Nervous System, vol. 27, no. 1, pp. 87-94, 2011.